The problem. By 2014 CRISPR papers were arriving faster than anyone could read them. A newcomer needed one place that laid out the mechanism, the design rules, and the range of uses without drowning in primary papers. Reviews like this exist to give a field a shared map.

The idea. The authors walk through how Cas9 finds and cuts DNA, why the PAM and the guide sequence set specificity, and where off-target cuts come from. They cover the practical levers: guide design, the nickase trick for lowering off-target damage, and dCas9 fusions for control and imaging. They then survey applications, from knockouts and knock-ins to screens and disease models, and are honest about the limits, chiefly specificity and delivery.

Why it matters. This is the orientation piece for the rest of this batch. Everything else I read today, the screens, Cpf1, base and prime editing, sits somewhere on the map this review draws. It is also a good model of what a well-aimed review does: it does not report new evidence, it makes an overwhelming literature usable.

Verdict. A clear, high-value orientation review, now dated on the newest tools but still the right first read. Use it to place the primary papers, not as evidence itself.